BIAFW and BIAF Related Headlines
Go Back- bioAffinity Technologies shows asthma therapy matching technology
- bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
- bioAffinity Technologies starts lung cancer test validation study
- bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
- bioAffinity's CyPath Lung test helps avoid biopsy in elderly patient case
- New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
- Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
- bioAffinity Technologies expands medical advisory board
- bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
- bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
- bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
- bioAffinity Technologies Reports Third Quarter 2025 Financial Results
- bioAffinity Technologies reports 111% jump in october lung test volume
- bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
- bioAffinity Technologies receives Australian patent acceptance
- bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
- bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
- bioAffinity Technologies receives US patent allowance for lung cancer test
- bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
- bioAffinity Technologies regains Nasdaq compliance requirements
- bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
- WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- bioAffinity Technologies closes $1.8 million stock offering
- bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- bioAffinity Technologies raises $1.8 million in registered direct offering
- WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- bioAffinity Technologies raises $1.8 million in registered direct offering
- bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- bioAffinity reports 95% quarterly jump in lung cancer test sales
- bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
- bioAffinity Technologies closes $4.8 million public offering
- WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
- bioAffinity Technologies closes $4.8 million public offering
- bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
- bioAffinity Technologies prices $4.8m public offering at $2.50 per share
- WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
- bioAffinity Technologies prices $4.8 million public offering
- bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
- bioAffinity shares case studies showing CyPath Lung test detected stage 1A cancer
- bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
- bioAffinity Technologies executes 1-for-30 reverse stock split
- bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
- Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
- U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
- bioAffinity Technologies adds two new board members
- bioAffinity Technologies Appoints New Members to Board of Directors
- bioAffinity Technologies closes private placement for $1.2 million
- bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
- bioAffinity Technologies Reports Second Quarter 2025 Results
- bioAffinity Technologies raises $1.2 million in private placement
- WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
- bioAffinity Technologies prices private placement for $1.2 million
- bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
- bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
- Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
- Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
- bioAffinity Technologies receives Canadian patent for lung cancer test
- Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
- bioAffinity Technologies receives China patent for lung cancer diagnostic
- bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
- Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
- bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
- bioAffinity (BIAF) receives patent grant from CNIPA
- bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
BIAFW and BIAF Related Press Releases
Go Back- bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
- bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
- New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
- Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
- bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
- bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
- bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
- bioAffinity Technologies Reports Third Quarter 2025 Financial Results
- bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
- bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
- bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
- bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
- bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
- WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
- WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
- bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
- WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
- bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
- bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
- bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
- Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
- U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
- bioAffinity Technologies Appoints New Members to Board of Directors
- bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
- bioAffinity Technologies Reports Second Quarter 2025 Results
- WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
- bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
- bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
- Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
- Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
- Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
- bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
- Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
- bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
- bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
